⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Replicor Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Replicor Inc.
↗Montreal, Canada
Replicor Inc. is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada, dedicated to developing a functional cure for chronic hepatitis B (HBV) and hepatitis delta (HDV) infections. The company specializes in a novel class of therapeutics called Nucleic Acid Polymers (NAPs), which are designed to block the assembly of HBV subviral particles and inhibit viral replication.
The company's lead candidate, REP 2139-Mg, has demonstrated potent antiviral effects in clinical trials, including the ability to achieve HBsAg clearance and functional cure in patients. Replicor operates as a private entity and has focused its efforts on clinical development, including compassionate access programs and proof-of-concept Phase II trials across North America, Europe, and Asia.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Viral Hepatitis Therapeutics
SIZE & FINANCIALS
Employees:51-200
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Series A
Investors:Venrock
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Nucleic Acid Polymers (NAPs)
Active Trials:1
Trial Phases:Phase 2: 4
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Institute Armand Frappier (Research collaboration), University Hospital at the University of Duisburg-Essen (Research collaboration)
COMPETITION
Position:Niche Player
Competitors:Assembly Biosciences, Vir Biotechnology, Bluejay Therapeutics, Ribocure Pharmaceuticals
LEADERSHIP
Key Executives:
Michel Bazinet - CEO & Chief Medical Officer
Andrew Vaillant - Chief Scientific Officer
Nicolas Tétrault - President
Board Members:Robert C. Bryce, John Bai
LINKS
Website:replicor.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Replicor Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.